Early Treatment Cuts Relapse Risk in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease
Dr. Rae Bacharach discusses the Neurology Today article, "Early Treatment Cuts Relapse Risk in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease," by Gina Shaw, available in the latest…
Read the full articleYou might also wanna read
Q&A 168 - Is it a relapse on ofatumumab?
The question of whether this is a new relapse or the emergence of smouldering MS in a pathway with reduced reserve is difficult without exam
Anti-nephrin antibodies are not enriched in patients with primary and posttransplant recurrent podocytopathies
BACKGROUND Anti-nephrin autoantibodies have emerged as a putative pathogenic driver in a subset of patients with podocytopathies, including
Efficacy and Safety of Low-Dose Blinatumomab in the Treatment of Refractory Autoimmune Encephalitis and Autoimmune Cerebellitis
Conditions : Autoimmune Encephalitis (AE); Autoimmune Cerebellitis Interventions : Drug: Blinatumomab Sponsors : Beijing Tiantan Hospital No
An Exploratory Study of Obinutuzumab β in the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Conditions : Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP); Obinutuzumab β Interventions : Drug: Obinutuzumab β Sponsors
Senolytic treatment linked to oligodendrocyte dysfunction and demyelination in brain study
Aging is a primary risk factor for disease progression in multiple sclerosis (MS). Because of this, treatments that can reduce the consequen
pnas.org·1mo ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.